Cargando…

Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy

Cardiomyopathy is a leading cause of death for Duchenne muscular dystrophy. Here, we find that the mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) can share common ligands but play distinct roles in dystrophic heart and skeletal muscle pathophysiology. Comparisons of their ligand st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heier, Christopher R, Yu, Qing, Fiorillo, Alyson A, Tully, Christopher B, Tucker, Asya, Mazala, Davi A, Uaesoontrachoon, Kitipong, Srinivassane, Sadish, Damsker, Jesse M, Hoffman, Eric P, Nagaraju, Kanneboyina, Spurney, Christopher F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Life Science Alliance LLC 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371196/ https://www.ncbi.nlm.nih.gov/pubmed/30745312 http://dx.doi.org/10.26508/lsa.201800186

Ejemplares similares

Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone
por: Fiorillo, Alyson A., et al.
Publicado: (2018)

Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice
por: McCormack, Nikki M., et al.
Publicado: (2023)

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes
por: Hoffman, Eric P., et al.
Publicado: (2018)

Muscle Weakness in Myositis: MicroRNA‐Mediated Dystrophin Reduction in a Myositis Mouse Model and Human Muscle Biopsies
por: Kinder, Travis B., et al.
Publicado: (2020)

A mouse model of inherited choline kinase β-deficiency presents with specific cardiac abnormalities and a predisposition to arrhythmia
por: Tavasoli, Mahtab, et al.
Publicado: (2022)

Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
por: Hoffman, Eric P., et al.
Publicado: (2019)

Omigapil Treatment Decreases Fibrosis and Improves Respiratory Rate in dy(2J) Mouse Model of Congenital Muscular Dystrophy
por: Yu, Qing, et al.
Publicado: (2013)

Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy
por: Capogrosso, Roberta Francesca, et al.
Publicado: (2018)

Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping Therapy
por: Novak, James S., et al.
Publicado: (2021)

Non-Invasive MRI and Spectroscopy of mdx Mice Reveal Temporal Changes in Dystrophic Muscle Imaging and in Energy Deficits
por: Heier, Christopher R., et al.
Publicado: (2014)

Membrane Sealant Poloxamer P188 Protects Against Isoproterenol Induced Cardiomyopathy in Dystrophin Deficient Mice
por: Spurney, Christopher F, et al.
Publicado: (2011)

OPN‐a induces muscle inflammation by increasing recruitment and activation of pro‐inflammatory macrophages
por: Many, Gina M., et al.
Publicado: (2016)

Mechanism of action and therapeutic route for a muscular dystrophy caused by a genetic defect in lipid metabolism
por: Tavasoli, Mahtab, et al.
Publicado: (2022)

Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease
por: Heier, Christopher R, et al.
Publicado: (2016)

Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice
por: Ziemba, Michael, et al.
Publicado: (2021)

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2017)

The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice
por: Almeida, Luis E. F., et al.
Publicado: (2018)

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018)

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018)

VBP15, a Glucocorticoid Analogue, Is Effective at Reducing Allergic Lung Inflammation in Mice
por: Damsker, Jesse M., et al.
Publicado: (2013)

Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor
por: Wells, Elizabeth, et al.
Publicado: (2016)

Glucocorticoid-Treated Mice Are an Inappropriate Positive Control for Long-Term Preclinical Studies in the mdx Mouse
por: Sali, Arpana, et al.
Publicado: (2012)

Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy
por: Grounds, Miranda D., et al.
Publicado: (2023)

Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
por: Mah, Jean K., et al.
Publicado: (2022)

The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse
por: Zhang, Aiping, et al.
Publicado: (2015)

Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
por: Smith, Edward C., et al.
Publicado: (2020)

Single-cell transcriptomic analysis of the identity and function of fibro/adipogenic progenitors in healthy and dystrophic muscle
por: Uapinyoying, Prech, et al.
Publicado: (2023)

Emerging Therapies for Dystrophic Cardiomyopathy
por: Garry, Daniel J., et al.
Publicado: (2019)

Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis
por: Elhalag, Rowan H., et al.
Publicado: (2023)

Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse
por: Spurney, Christopher F., et al.
Publicado: (2010)

Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial
por: Guglieri, Michela, et al.
Publicado: (2022)

Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs
por: Fiorillo, Alyson A., et al.
Publicado: (2020)

Mitochondrial dysfunction and consequences in calpain-3-deficient muscle
por: Jahnke, Vanessa E., et al.
Publicado: (2020)

Dystrophic cardiomyopathy: role of the cardiac myofilaments
por: George, Thomas G., et al.
Publicado: (2023)

Speckle tracking analysis of the left ventricular anterior wall shows significantly decreased relative radial strain patterns in dystrophin deficient mice after 9 months of age
por: Spurney, Christopher, et al.
Publicado: (2012)

The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice
por: Sali, Arpana, et al.
Publicado: (2013)

Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children
por: Hathout, Yetrib, et al.
Publicado: (2016)

Elusive sources of variability of dystrophin rescue by exon skipping
por: Vila, Maria Candida, et al.
Publicado: (2015)

Deletion of miR-146a enhances therapeutic protein restoration in model of dystrophin exon skipping
por: McCormack, Nikki M., et al.
Publicado: (2023)

Editorial: Genome and transcriptome editing to understand and treat neuromuscular diseases
por: Maruyama, Rika, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3hef6n7mu2cru4qf0qc80694cv